Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pathol Oncol Res. 2013 Jul;19(3):509-13. doi: 10.1007/s12253-013-9610-8. Epub 2013 Mar 12.

Measurement of HER2 in saliva of women in risk of breast cancer.

Author information

  • 1Laboratório de Genética Aplicada, Serviço de Hematologia, Instituto Nacional de Câncer, Pç da Cruz Vermelha, 23, 6º Andar, Rio de Janeiro, Brazil.

Abstract

HER2 amplification can be present in ductal carcinoma in situ (DCIS). The aim of the present study was to test the feasibility of measuring soluble HER2 in the saliva of patients at risk of breast cancer towards early diagnosis and prognosis. Women with lesions classified as 4 according to BIRADS and women with spontaneous nipple discharge (NAF) were recruited for this study. Quantification of soluble HER2 in saliva was performed using the enzyme immunoassay ELISA. Median values of HER2 were quantified in saliva of the control groups and in the patient groups. The statistical test nonparametric Mann-Whitney was applied for the evaluation of median differences. Although the medians increased with the severity of the clinical status, no significant difference was found in all possibilities (p > 0.05) when comparing the medians among the patients groups. Interestingly, inter-individual HER2 quantity variations in the saliva were detected in this study in some subjects from each group. Considering possible inter-individual variations, research on saliva-based circulating HER2 has to be reinforced to ensure its correct application in diagnosis, treatment and in follow-up of breast cancer patients. Older and current issues surrounding the controversy about the appropriate methods for HER2 evaluation are discussed.

PMID:
23479082
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk